Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

A study in healthy men to test how different doses of BI 3031185 are tolerated and how food influences the amount of BI 3031185 in the blood Ended

2023-507941-28-00 Healthy volunteer trial 2024-03-08
A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789… Ended

2023-506354-20-00 Small Cell Lung Cancer and Neuroendocrine Carcinoma 2024-02-20
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple doses Ended

2023-507882-24-00 Inflammatory Gastrointestinal Disease 2024-02-20
A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or M… Ended

2023-507321-42-00 Myelodysplastic syndrome (MDS) 2024-02-15
A Phase 1 Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors Ended

2023-504896-26-00 Advanced Stage Solid Tumors 2024-02-09
Testing for the first time the effects of a new medicine in healthy people Ended

2023-507880-20-00 Psychatric disorder 2024-02-05
A research study of a new medicine (NNC0650-0013) in healthy men Ended

2023-506134-79-00 Weight management, Diabetes mellitus type 2; healthy su 2024-01-23
[HIBOU] : A phase I, single-center, randomized, double-blind, single-dose escalation, placebo-controlled clinical study to evaluate the safe… Ended

2023-509035-30-00 Antidote 2024-01-18
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3… Ended

2023-505322-34-00 Advanced or metastatic solid tumors 2024-01-08
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of thr… Ended

2023-506396-94-00 Sarbecovirus diseases 2024-01-08
Study on the investigational drug IAMA-6, placebo-controlled, administered to healthy adult volunteers, at single oral doses and at multiple… Ended

2023-507454-33-00 Neurodevelopmental disorder 2024-01-08
A study to evaluate the safety, tolerance and changes in blood levels of an anti-toxin drug (FBT-002) in healthy male and female subjects Ended

2023-505745-16-00 Antidote 2024-01-05
A study to evaluate the safety, tolerability and distribution of TB0010 in head and neck squamous cell carcinoma Ended

2024-517779-19-00 EGFR-Positive Head and Neck Squamous Cell Carcinoma 2024-01-05
Safety, tolerability, pharmacokinetics and pharmacodynamics of ARV-102 in healthy participants Ended

2023-507910-28-00 Parkinson's Disease 2024-01-04
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma. Ended

2023-503739-16-00 Relapsed or refractory solid tumors or non-Hodgkin lymp 2023-12-20
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors Ended

2022-502348-11-00 Pancreatic Neoplasms 2023-12-15
A research study looking at how the compound NNC0194-0499 works with birth control pills in women not able to bear children. Ended

2023-503595-24-00 Healthy volunteers (Non-alcoholic steatohepatitis (NASH 2023-12-14
A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and… Ended

2023-503577-38-00 Atopic Dermatitis 2023-12-07
A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess th… Ended

2023-505542-26-00 Heart failure (HF) 2023-11-30
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination with a Checkpoint Inhibitor with or without Stand… Ended

2022-502615-11-00 Locally Advanced or Metastatic Solid Tumors 2023-11-29
A trial to learn if different doses of REGN17092 are safe in healthy adults Ended

2023-505041-52-00 SARS-CoV-2 (COVID-19) 2023-11-28
AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEW… Ended

2023-504545-31-00 colorectal cancer 2023-11-23
A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD) Ended

2024-511770-76-00 Alzheimer's disease 2023-10-31
A study in healthy men to test how well different doses of BI 3802876 are tolerated Ended

2023-504538-23-00 Healthy volunteer trial 2023-10-24